Full Prescribing Information

  • EVOCLIN® (clindamycin phosphate) Foam, 1% is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, or a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis, including pseudomembranous colitis.

  • Prescribe with caution in atopic individuals.

  • Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritation or dermatitis occurs, EVOCLIN Foam should be discontinued.

  • Diarrhea, bloody diarrhea, and pseudomembranous colitis have been reported with systemic and rarely with topical clindamycin. Discontinuation is recommended if significant diarrhea develops.

  • In clinical trials, the most common adverse events were headache (3%) and application-site reactions, including burning (6%), itching (1%), and dryness (1%).

  • The contents of EVOCLIN Foam are flammable; patients should avoid fire, flame, and/or smoking during and immediately following application.

EVOCLIN Foam is indicated for topical application in the treatment of acne vulgaris in patients 12 years and older.